Pharmalicensing.com Send to a colleague
12th May 2008

Welcome to this week's news update...

Biotechnology

Human Papillomavirus microRNA diagnostics and therapeutics
Uses of a p53 specific microRNA (miRNA): It has been reported that the tumor suppressive mRNA miR-34a (a downstream target of p53) is downregulated in HPV-infected primary keratinocytes more

Central Nervous System

A genetic diagnostic test for 'early-onset Alzheimer's disease'
SNP's in the human act gene correlates well with susceptibility to early-onset Alzheimer's Disease. Researchers have developed a test that could determine the presence of SNP's, which would allow therapeutic treatments to begin early more
 

Dermatological

Atopiclair - innovative non-steroidal cream for atopic dermatitis
New cream formulation to manage the symptoms of atopic dermatitis more

Diagnostic

Human and improved murine monoclonal antibodies against CD22
Two anti-CD22 antibodies of human origin have been generated; each has the ability to recognize CD22 on the surface of Raji cells more
Segmenting colon wall via level set techniques
A level set based method to determine, from a CT colonography (CTC) scan, the location of the colon serosal tissue boundary: After determining this location, the algorithm segments the entire colon wall at subvoxel accurate precision more
 

Drug discovery

Microarray binding sensors using carbon nanotube transistors
Unique distinctions of this design over other CNT based methods: complete isolation of the CNTs from chemical reactions concomitant with probe immobilization and target capture, and the CNTs functioning only as charge sensors more

Gastrointestinal

GL1001
GL1001 is a novel, clinical-stage small molecule drug candidate for the treatment of inflammatory diseases of the gastrointestinal tract more

Genito-urinary

Therapy for nephrogenic systemic fibrosis and scleroderma: Rapamycin inhibition of the phospho-70-ribosomal S6-kinase (08-23)
New use of rapamycin to treat nephrogenic systemic fibrosis and scleroderma more

Immune related disorders

LPCN 1019: Immunosuppressant ANDA opportunity
Immunosupressant product, bioequivalent to reference product more
 

Infectious diseases

Treatment to destroy virus particles
Academics at the University of Nottingham have invented a new method to inactivate viruses without affecting valuable blood and plasma proteins more

Musculoskeletal

BIS010, Semi-synthetic polysaccharide for the treatment of musculoskeletal and chronic inflammatory disorders including osteoarthritis and cartilage degeneration
BIS010 is a semi-synthetic plant origin polysaccharide demonstrating a potential modifying effect of the biologic activity of the joints more
Cartisorb ® (Glucosamine Sulfate sachets) - CTD dossier ready for registration
BIOIBERICA would extend the right to use its CTD dossier for registration of Cartisorb® (Glucosamine Sulfate sachets) as a branded generic drug (to be marketed under Cartisorb® brand name or other brand name) on a local level more

Oncology

Human monoclonal antibody against mesothelin
An anti-mesothelin antibody of human origin has been generated; it has the ability to efficiently recognize mesothelin on the surface of cells, and induce ADCC in mesothelin-positive cells more
 

Respiratory

LPCN 1035: Longer acting version of a leading respiratory product
LPCN 1035 is being developed as a longer acting version of a leading respiratory product, specifically as a non-sedating, non-narcotic anti-tussive more

Dermatological 

In-licensing of a dermal fillers
Dermal fillers with long lasting facial sculpting effect more 

Hospital and Surgery

Partners/companies looking for a strategic partnership to give them privileged access to hospital markets in Europe
LFB is seeking partners/companies which are looking for a strategic partnership to give them privileged access to hospital markets in Europe, ideally having a synergistic presence in North America or South East Asia more
Seeking in licensing opportunities for Europe with a priority for France, Germany and UK for products ready to market in hospitals or under clinical development
LFB is looking for alliances or in-licensing opportunities as the European arm for products ready to market or under clinical development, addressing severe diseases treated in hospitals more
 

Sensory organ

Licensing opportunities in ophthalmology drugs or therapeutic devices
Ophthalmology drugs or therapeutic devices more
DESMA PHARMA Group manufactures and markets proprietary, branded, ethical and OTC products in more than 40 Countries worldwide
Goldshield is a global pharmaceutical and healthcare company headquartered in the UK, seeking new product opportunities in the following areas: Cardiology, ophthalmology, dermatology & urology
Macleods Pharma is vertically integrated pharmaceutical company with our own API R&D & production facility, Formulation R&D & 6 production facilities
Neuromed is a biopharmaceutical company developing new and improved pain therapies. Our goal is to create a better future for people who suffer from chronic pain
Ore Pharmaceuticals is a commercial drug development company
Liquid transdermal drug delivery technology licensing, OTC topical analgesics, and cosmetics
WORLDiscoveriesTM, a new technology transfer consortium formed by London's research institutions, will develop small- and medium-sized enterprises in the region, creating 250 jobs and generating $50 million in investment over the next three years
Robarts Research Institute scientist Paula Foster and Schulich School of Medicine & Dentistry's David Litchfield will receive more than $885,000 to fund innovative research projects
Innocoll announces dosing of first patient in US Phase 2 clinical trial to investigate CollaRx® GENTAMICIN TOPICAL for the prevention of diabetic foot infections
The Exadoral oral dispenser range is one of the latest supplements to B. Braun's range of products helping reduce the potential for medication errors, improve best practice and meet patient safety needs
However, Somaxon's Silenor will replace Ambien as the clinical gold standard for Insomnia in 2011, according to a new report from Decision Resources
Scientists at the Lawson Health Research Institute (Lawson) in London are currently testing new treatments aimed at reducing or eliminating the capacity of cancer cells to get around the immune system
Avastin used in combination with Taxol and Paraplatin will become the clinical gold standard treatment by 2011, according to a new report from Decision Resources

PharmaFinance 2008

22 - 23 May 2008 — Rome, Italy

A unique two-day intensive approach to find and to offer: AIC, patents & licensing, co-Marketing of Bio-Nano-Pharma Technologies. Pharma Finance 2008 is specifically designed to support in-depth partnership and collaboration development

Event details  

Email event organizer

PharmaBiotech IP Summit

28 - 30 May 2008 — Philadelphia, USA

The event balances the challenges of IP protection, enforcement and management providing both strategic and actionable insights through case studies and interactive session formats. Secure your place now at PharmaBiotech IP Summit.

Event details

Email event organizer


Pharmalicensing Ltd
Marlborough House, 1st Floor,
Westminster Place,
York Business Park, YO26 6RW.
United Kingdom
Email: info@pharmalicensing.com

If you no longer wish to receive this newsletter please unsubscribe



Pharmalicensing Ltd
is a division of
UTEK Corporation